Company news

Black Diamond Therapeutics, Inc. news in 2026

Black Diamond Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

November 12, 2026

Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update

November 10, 2026

Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC

November 9, 2026

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 2, 2026

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 5, 2026

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

May 21, 2026

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

May 19, 2026

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

April 20, 2026

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 16, 2026

Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer

January 28, 2026